scholarly journals The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

2020 ◽  
Vol 11 (4) ◽  
pp. 932-939 ◽  
Author(s):  
Junshang Ge ◽  
Jie Wang ◽  
Hui Wang ◽  
Xianjie Jiang ◽  
Qianjin Liao ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid

scholarly journals Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

2020 ◽  
Vol 10 (2) ◽  
pp. 52
Author(s):  
Andra Piciu ◽  
Maria-Iulia Larg ◽  
Doina Piciu
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Genetic Mutation ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Early Assessment ◽  
Pet Ct ◽  
Ct Evaluation

In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.

BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer

2012 ◽  
Vol 20 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Gina M. Howell ◽  
Marina N. Nikiforova ◽  
Sally E. Carty ◽  
Michaele J. Armstrong ◽  
Steven P. Hodak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Papillary Thyroid Cancer ◽  
Central Compartment ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Node Metastasis

Association of TIMP-3 expression and BRAF V600E mutation status in papillary thyroid cancer

2017 ◽  
Author(s):  
Maryam Zarkesh ◽  
Mehdi Hedayati ◽  
Azita Zadeh-Vakili ◽  
Afsoon Daneshafrooz ◽  
S Adeleh Razavi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Mutation Status

Abstract 3829: DNA methylation profile in papillary thyroid cancer according to BRAF (V600E) mutation

2015 ◽  
Author(s):  
Caroline Moraes Beltrami ◽  
Mariana Bisarro dos Reis ◽  
Mateus Camargo Barros-Filho ◽  
Fabio Albuquerque Marchi ◽  
Hellen Kuasne ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf V600e Mutation ◽  
Methylation Profile ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Dna Methylation Profile

Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer

2017 ◽  
Vol 42 (1) ◽  
pp. 114-122 ◽  
Author(s):  
Jae Won Chang ◽  
Ki Wan Park ◽  
Jae Hyung Heo ◽  
Seung-Nam Jung ◽  
Lihua Liu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
18F Fluorodeoxyglucose

Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer

Surgery ◽  
2015 ◽  
Vol 157 (1) ◽  
pp. 119-125 ◽  
Author(s):  
Séverine M. Niederer-Wüst ◽  
Wolfram Jochum ◽  
Diana Förbs ◽  
Michael Brändle ◽  
Stefan Bilz ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Risk Scores ◽  
Papillary Thyroid ◽  
Mutation Status ◽  
Clinical Risk

scholarly journals Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer

Surgery ◽  
2013 ◽  
Vol 154 (6) ◽  
pp. 1239-1245 ◽  
Author(s):  
Linda A. Dultz ◽  
Shumon Dhar ◽  
Jennifer B. Ogilvie ◽  
Keith S. Heller ◽  
Dafna Bar-Sagi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Therapeutic Implications

BRAF V600E Mutation in Papillary Thyroid Cancer and Its Effect on Postoperative Radioiodine ( 131 I) Therapy: Should We Modify Our Therapeutic Strategy?

2018 ◽  
Vol 96 (5) ◽  
pp. 276-282
Author(s):  
Maite Domínguez Ayala ◽  
Amaia Expósito Rodríguez ◽  
Amaia Bilbao González ◽  
Pablo Mínguez Gabiña ◽  
Teresa Gutiérrez Rodríguez ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Therapeutic Strategy ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document